Eli Lilly’s experimental Alzheimer’s drug donanemab can modestly slow the worsening of the disease by about four to seven months, according to researchers. Source
Eli Lilly’s experimental Alzheimer’s drug donanemab can modestly slow the worsening of the disease by about four to seven months, according to researchers. Source